文献速递垂体与肾上腺疾病

艾迪生病患者的内脏脂肪与心血管疾病新型生物标志物:一项病例对照研究

Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case-Control Study.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本横断面单中心病例对照研究纳入76例艾迪生病患者与76名按性别、年龄、体重指数和吸烟习惯匹配的健康对照,采用计算机断层扫描测量内脏腹部脂肪组织,并评估代谢综合征患病率及92种心血管疾病生物标志物。结果示两组内脏脂肪无差异,但患者代谢综合征患病率更高(34% vs 16%,P=0.01),且17种生物标志物存在显著差异。

要点

  • 艾迪生病患者内脏脂肪与匹配健康对照无差异。
  • 患者代谢综合征患病率为34%,高于对照的16%(P=0.01)。
  • 92种生物标志物中17种在患者与对照间存在显著差异。

核心结论

  • 尽管艾迪生病患者皮质醇暴露更高,其内脏脂肪并未增加。
  • 艾迪生病患者代谢综合征患病率升高,且多种心血管疾病生物标志物受到不良影响。

研究设计与样本

  • 横断面、单中心、病例对照研究,纳入76例艾迪生病患者(51例女性)和76名按性别、年龄、体重指数和吸烟习惯匹配的健康对照。
  • 主要结局变量为计算机断层扫描测量的内脏腹部脂肪组织,次要结局变量为代谢综合征患病率和92种心血管疾病生物标志物。
  • 所有受试者平均年龄53±14岁,平均体重指数25±4 kg/m2,艾迪生病平均病程17±12年。

主要发现

  • 氢化可的松日剂量中位数(范围)为30 mg(10至50 mg)。
  • 24小时尿游离皮质醇排泄中位数(四分位距)患者组为359 nmol(193至601 nmol),对照组为175 nmol(140至244 nmol),P<0.001。
  • 内脏腹部脂肪组织两组间无差异。
  • 经多重检验校正后,92种生物标志物中有17种在患者与对照间存在显著差异;炎症性、促炎性和促动脉粥样硬化风险生物标志物在患者中升高(倍数变化>1),血管舒张保护性标志物降低(倍数变化<1)。
  • 代谢综合征患病率患者组为34%(26例),对照组为16%(12例),P=0.01。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with Addison's disease (AD) have increased cardiovascular mortality. OBJECTIVE: To study visceral fat and conventional and exploratory cardiovascular risk factors in patients with AD. DESIGN: A cross-sectional, single-center, case-control study. SUBJECTS: Patients (n = 76; n = 51 women) with AD and 76 healthy control subjects were matched for sex, age, body mass index (BMI), and smoking habits. MAIN OUTCOME MEASURES: The primary outcome variable was visceral abdominal adipose tissue (VAT) measured using computed tomography. Secondary outcome variables were prevalence of metabolic syndrome (MetS) and 92 biomarkers of cardiovascular disease. RESULTS: The mean ± standard deviation age of all subjects was 53 ± 14 years; mean BMI, 25 ± 4 kg/m2; and mean duration of AD, 17 ± 12 years. The median (range) daily hydrocortisone dose was 30 mg (10 to 50 mg). Median (interquartile range) 24-hour urinary free cortisol excretion was increased in patients vs controls [359 nmol (193 to 601 nmol) vs 175 nmol (140 to 244 nmol); P < 0.001]. VAT did not differ between groups. After correction for multiple testing, 17 of the 92 studied biomarkers differed significantly between patients and control subjects. Inflammatory, proinflammatory, and proatherogenic risk biomarkers were increased in patients [fold change (FC), >1] and vasodilatory protective marker was decreased (FC, <1). Twenty-six patients (34%) vs 12 control subjects (16%) fulfilled the criteria for MetS (P = 0.01). CONCLUSION: Despite higher cortisol exposure, VAT was not increased in patients with AD. The prevalence of MetS was increased and several biomarkers of cardiovascular disease were adversely affected in patients with AD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bergthorsdottir R, Ragnarsson O, Skrtic S, et al. Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case-Control Study. J Clin Endocrinol Metab. 2017. PMID: 28945861. doi:10.1210/jc.2017-01324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。